Last reviewed · How we verify
Octyl Dimethyl Paba (Padimate O)
Octyl Dimethyl Paba (generic name: Padimate O) is a drug. It is currently FDA-approved.
At a glance
| Generic name | Padimate O |
|---|---|
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clinical Study to Evaluate the 80-Minute Water Resistant Sun Protection Factor (SPF) of Sunscreen Products (NA)
- Clinical Study to Evaluate the Sun Protection Factor (SPF) of Three Sunscreen Products (NA)
- Clinical Study to Evaluate the Sun Protection Factor (SPF) of Sunscreen Products (NA)
- A Sunscreen Based on Bioadhesive Nanoparticles (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Octyl Dimethyl Paba CI brief — competitive landscape report
- Octyl Dimethyl Paba updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Octyl Dimethyl Paba
What is Octyl Dimethyl Paba?
Octyl Dimethyl Paba (Padimate O) is a pharmaceutical drug.
What is the generic name of Octyl Dimethyl Paba?
Padimate O is the generic (nonproprietary) name of Octyl Dimethyl Paba.
What development phase is Octyl Dimethyl Paba in?
Octyl Dimethyl Paba is FDA-approved (marketed).
Related
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Dermatology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing